Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
193
resultados
Última actualización
08/12/2025 [06:50:00]
Resultados 25 a 50 de 193
Resumen de: WO2025250539A1
The present invention provides a pharmaceutical composition capable of delivering therapeutic agents such as nucleic acids to the lung via systemic administration to treat lung-related diseases. Said composition comprises a non-covalent complex formed by co-precipitating a sialic acid (SA) entity, a complexing agent, and a nucleic acid cargo.
Resumen de: WO2025250244A1
The disclosure provides particles, including anisotropic particles, and compositions, methods and kits thereof that are useful, e.g., for delivering an agent or in treating or preventing diseases, such as proliferative diseases. The disclosure also provides methods of preparing plurality of such particles and liposomes that provide control over size and morphology.
Resumen de: WO2025249682A1
The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.
Resumen de: WO2025249687A1
The present invention relates to a method for producing extracellular vesicles into which a therapeutic gene is introduced by electroporation, a wound-healing pharmaceutical composition produced by the method, and a wound-healing pharmaceutical preparation or quasi-drug preparation comprising same as an active ingredient. The extracellular vesicles derived from mesenchymal stem cells (MSCs), fibroblasts, and colostrum, produced by the present method, are all non-cytotoxic, have excellent nucleic acid delivery efficiency, and thus allow for stable expression. In particular, by introducing a vascular endothelial growth factor (VEGF) gene, which is known to have a wound-healing effect, into extracellular vesicles derived from mesenchymal stem cells (MSCs), fibroblasts, and colostrum through electroporation, VEGF gene-introduced extracellular vesicles produced by the production method of the present invention can be used as a gene therapy agent for wound healing.
Resumen de: WO2025248298A1
The present invention provides nano-formulation of Curcumin having nano Curcumin content up to 10% w/w in formulation (up to 90 mg) with 100% solubility in water, - and particle size less than 100 nm with good bioavailability through enhanced permeability and stability, thereby increase in their effectiveness for various therapeutic uses. The nano-formulation of Curcumin is having low particle size and increased efficacy, stability against pH, light, temperature, and humidity.
Resumen de: WO2025245869A1
The present invention relates to an ionizable lipid molecule containing an arginine structure, lipid nanoparticles comprising same, and use thereof. Specifically, provided are an ionizable lipid molecule represented by formula (1) containing a structure of arginine and a derivative thereof, lipid nanoparticles comprising same, a preparation method therefor, and use thereof. Compared with ionizable lipid molecules conventionally used in the art, the lipid nanoparticles prepared from the ionizable lipid molecule represented by formula (1) of the present invention can achieve highly efficient delivery and expression of nucleic acids.
Resumen de: WO2025245652A1
Disclosed is a method for producing a hydrogel-type medical device, which comprises producing, in advance, copper nanoparticles coated with high-molecular-weight chitosan; and incorporating the particles during the final minutes of a step of crosslinking, which allows the coating to remain on the nanoparticles, preventing the dissolution thereof, and the nanoparticles to be uniformly incorporated into the latticed formation of the hydrogel. Also disclosed are the hydrogel and the use thereof in different types of wounds, burns and ulcerations.
Resumen de: AU2024281393A1
Compositions and methods for enhancing payload-based gene therapy by increasing the percentage of payload delivered to a non-liver target in a subject by blocking binding of LDL to LDL receptors (LDLR) in the liver, and then administering a payload-based therapy targeting a non-liver tissue.
Resumen de: AU2024271802A1
The present disclosure relates generally to lipid nanoparticles (LNPs) and compositions comprising the same, and their use in delivery of agents, such as nucleic acid-based therapeutics, in particular to transfection recalcitrant cells and/or to lung tissue.
Resumen de: AU2024269259A1
In various aspects and embodiments provided are compositions containing extracellular vesicles (including modified extracellular vesicles), methods of making preparations of extracellular vesicles, methods of modifying extracellular vesicles and methods of using modified and/or unmodified extracellular vesicles.
Resumen de: WO2025250979A1
The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.
Resumen de: WO2025250906A1
The present invention relates to processes for preparing lipid nanoparticles having an antibody or fragment antibody binding region.
Resumen de: WO2025250729A1
The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).
Resumen de: AU2024251515A1
The present application relates to lipid nanoparticles containing a steroid compound, and the preparation and a use of the lipid nanoparticles. The lipid nanoparticles can be used to deliver effective loads (such as a nucleic acid) into non-liver organs such as the spleen for the treatment or prevention of certain diseases or conditions, particularly spleen-associated diseases.
Resumen de: WO2025250730A1
The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).
Resumen de: WO2025248434A1
A composition for topical use in the treatment of androgenetic alopecia comprises a nanoemulsion, said nanoemulsion comprising a mixture of oils, at least one surfactant, finasteride and minoxidil. The mixture of oils comprises sandalwood oil, rosemary oil and sweet almond oil.
Resumen de: WO2025247930A1
Nanoparticles (1) for administering at least one active ingredient (4), said nanoparticles comprising a magnetizable core (2), the core (2) having a shell (3) made of a polyphosphate and said shell (3) completely enclosing the core (2), characterized in that the shell (3) is mixed with an active ingredient (4).
Resumen de: WO2025247992A1
The invention relates to antigen-functionalized dextran-based nanoparticles capable of activating, functionally modifying, re-programming, and stimulating expansion of T cells, A pharmaceutical comprising the nanoparticles find use in the treatment of a medical condition requiring the activation and/or expansion of T-cells and/or in the production of receptor engineered-T cells used in such treatments.
Resumen de: WO2025247999A1
Method for the production of extracellular vesicles, EVs, loaded with a molecule of interest in a bioreactor containing a porous three-dimensional, 3D, scaffold, wherein the method comprises a seeding of the scaffold with a starting number of adherent immortalized cells resuspended after detachment, an attachment of the cells on said scaffold, an expansion of the cells on said scaffold up to a second number of adherent cells, defining a multiplication factor of at least 5 for a single expansion step, a production of EVs by said cells, a phase of loading said EVs with said molecule of interest, a harvest of EVs.
Resumen de: WO2025247843A1
The present invention relates to a pharmaceutical, dental and/or cosmetic composition comprising purified and/or isolated matrix derivative (EMD) proteins and a suitable pharmaceutical carrier, characterized in that the purified and/or isolated enamel matrix derivative (EMD) proteins comprised in said composition have a predominant MW of between 10-13kDa and an aggregation particle size of between 20-200 nm at Room Temperature (RT) and a pH of between 60-7.5. Said pharmaceutical, dental and/or cosmetic composition is disclosed for use in healing, restoration, enhancement and/or promotion of soft tissue in the oral cavity and/or craniomaxillofacial complex (CMF), in particular for use in treating patients suffering from a gingival deficiency and/or disorder. Preferably, the composition of the invention is administered via injection into the soft tissue in the oral cavity and/or the craniomaxillofacial complex (CMF) of the patient.
Resumen de: US2025367227A1
A folic acid-modified liposome-encapsulated tilianin nanocrystal (FA-Lipo@Til NC), and a preparation method and use thereof are provided. The FA-Lipo@Til NC includes a tilianin nanocrystal (Til NC) composition and a folic acid-modified phospholipid (FA-Lipo) bilayer encapsulated on a surface of the Til NC; where raw materials of the FA-Lipo bilayer include phospholipid, cholesterol (Chol), a methoxy poly(ethylene glycol)-cholesterol conjugate (mPEG-Chol), and a folic acid (FA) compound. The FA-Lipo@Til NC has a high drug loading capacity and a desirable stability. The inhibition of a Til dissolution behavior improves a penetration efficiency of the Til NC composition in intestinal mucus and an affinity with intestinal epithelial cells, thus effectively improving bioavailability of the Til.
Resumen de: US2025367331A1
Provided are a medical hydrogel containing ultrasonically-imageable bubble microspheres and a preparation method thereof. The medical hydrogel containing the ultrasonically-imageable bubble microspheres is formed by in-situ crosslinking of a polyethylene glycol precursor solution and a poly-amino crosslinker solution containing bubble microspheres, the polyethylene glycol precursor solution consisting of a multi-arm polyethylene glycol derivative and a buffer solution A.
Resumen de: US2025367305A1
The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.
Resumen de: US2025367333A1
According to one embodiment, a radiotherapy lipid nanoparticle includes a biodegradable lipid nanoparticle, and a radioactive material as an active ingredient. The radioactive material is bound to the biodegradable lipid nanoparticle and located outside of the biodegradable lipid nanoparticle.
Nº publicación: US2025367234A1 04/12/2025
Solicitante:
MITRANI MARIA INES [US]
MITRANI ALBERT [US]
BELLIO MICHAEL [US]
MITRANI MARIA INES,
MITRANI ALBERT,
BELLIO MICHAEL
Resumen de: US2025367234A1
Described herein are cell-free therapeutic compositions derived from blood or plasma and uses thereof for the treatment of selected diseases and disorders.
BOPI
Sede Electrónica
